Heart to Heart with Dr Michelle O'Donoghue

CANTOS: Dousing the Fire Within to Reduce CVD Dr O’Donoghue discusses preliminary results from the CANTOS trial of canakinumab, a unique anti-inflammatory agent which represents a new pathway for treating cardiovascular disease.
Experts And Viewpoints, August 07, 2017
A Personal Journey to a Plant-Based Diet A health crisis led Dr O'Donoghue to a plant-based diet. She asks why clinicians pay more respect to pills than dietary changes when poor diet affects not only heart disease but most western diseases.
Experts And Viewpoints, May 17, 2017
Should Cost of Therapy Be Considered in CV Guidelines? New cardio drugs, such as PCSK9 inhibitors and the angiotensin receptor neprilysin inhibitor, are expensive. Dr O'Donoghue asks whether that should affect guideline recommendations.
Experts And Viewpoints, March 06, 2017
'One Brave Idea' Recipient on Predicting Who Will Develop CAD Dr Calum MacRae, winner of the $75M One Brave Idea grant, explains to Dr O'Donoghue how he hopes to characterize biological differences between those who develop CAD and those who don't.
Experts And Viewpoints, January 26, 2017
Two Years After DAPT Trial, We're Still Debating Dr Michelle O'Donoghue asks for your opinion on the use of dual antiplatelet therapy beyond 1 year after stenting.
Experts And Viewpoints, October 19, 2016
When Not in Rome: Is It OK to Skip Scientific Conferences? As various outlets, such as theheart.org | Medscape, cover new research presented at meetings, are you still motivated to show up in person?
Experts And Viewpoints, September 20, 2016
Cardiologists Need to Pay Attention to Diabetes Meds Data from EMPA-REG and LEADER suggest that type 2 diabetes drugs can positively affect cardiovascular health. Cardiologists should pay attention, says Dr Michelle O'Donoghue.
Experts And Viewpoints, July 12, 2016
Are All Relationships With Industry Inherently Bad? Is the growing backlash that physicians and trialists face in their relationships with industry warranted in all cases?
Experts And Viewpoints, May 25, 2016
Off-Label Marketing: Who Should Decide What's Truthful? Dr Michelle O'Donoghue asks you to weigh in on a recent court case that could inform how Big Pharma markets drugs.
Experts And Viewpoints, March 23, 2016
Do We Need a Title IX for Clinical Trials? Women are still underrepresented in cardiovascular trials. Will we be able to adequately power such trials to address safety and efficacy in women and other underrepresented groups?
Experts And Viewpoints, February 12, 2016
What Influences Your Therapeutic Choices? Regional variation in therapeutic decision-making and clinical practice prompts Dr O'Donoghue to question what affects her choices.
Experts And Viewpoints, January 04, 2016
EMPA-REG, PCSK9s, and the Future of Clinical Trials Dr Michelle O'Donoghue interviews Dr Marc Sabatine about the EMPA-REG OUTCOME trial from AHA, the latest on PSCK9 inhibitors, and how clinical trials will be conducted in the future.
Experts And Viewpoints, December 14, 2015
Reconciling SPRINT and ACCORD: Dr Marc Sabatine Interviewed Dr Michelle O'Donoghue interviews Dr Marc Sabatine about the practice-changing SPRINT clinical trial from AHA.
Experts And Viewpoints, November 19, 2015

No Results